Finding Long-Term Value in Medication-Assisted Treatment for Opioid Use Disorder

Community Service Board of Middle Georgia (CSBMG)

As communities across the nation continue to address the opioid crisis, healthcare systems and behavioral health organizations are increasingly recognizing the importance of medication-assisted treatment (MAT), also referred to as medications for opioid use disorder (MOUD). Research continues to demonstrate that MOUD not only improves recovery outcomes for individuals living with opioid use disorder (OUD), but also reduces overall healthcare costs through decreased emergency department visits, hospitalizations, and treatment disengagement (Oss, 2026).

For organizations like CSBMG, these findings reinforce the importance of developing comprehensive and sustainable treatment models that support long-term recovery while improving community health outcomes. Individuals struggling with opioid addiction often face complex challenges that include co-occurring mental health disorders, housing instability, trauma exposure, unemployment, and repeated healthcare utilization. Addressing these concerns requires integrated systems of care that extend beyond short-term intervention.

According to Oss (2026), consumers who did not receive MOUD experienced more than double the annual total cost of care compared to individuals who adhered to extended-release buprenorphine treatment. Consumers not utilizing MOUD averaged approximately $67,290 annually in healthcare costs, while individuals adherent to extended-release buprenorphine averaged approximately $31,519 annually. These cost reductions were largely associated with fewer emergency department visits, reduced inpatient admissions, and decreased utilization of detoxification services.

Emergency department utilization remains one of the largest drivers of healthcare costs among individuals with untreated OUD. Oss (2026) reported that 45.5% of individuals not receiving MOUD required emergency department services during the study year, while only 24.5% of consumers adherent to extended-release buprenorphine experienced emergency department utilization. This illustrates how consistent engagement in treatment can improve both individual outcomes and healthcare system efficiency.

Healthcare leaders are increasingly encouraged to examine where treatment engagement tends to decline within the continuum of care. High-risk transition points often include emergency department discharge, psychiatric hospitalization discharge, residential treatment step-down, release from correctional facilities, and repeated outpatient treatment failure (Oss, 2026). These moments represent critical opportunities for organizations to strengthen consumer engagement and improve treatment continuity.

Long-acting injectable medications for opioid use disorder (LAI MOUD) have emerged as a promising strategy for improving treatment adherence among high-risk populations. Dr. Charles Whitehill noted that many individuals experiencing opioid addiction face only a brief “window of opportunity” for treatment engagement, particularly in emergency department settings where overdose risk remains high (Oss, 2026). Long-acting injectable medications may help reduce relapse risk by eliminating some of the barriers associated with daily medication management and inconsistent treatment participation.

Successful implementation of these treatment models also requires substantial organizational preparation. Clinical teams must receive training regarding medication administration, referral pathways, appropriate patient selection, and workflow redesign. Oss (2026) emphasized that healthcare organizations should approach the implementation of LAI MOUD as a significant change initiative requiring collaboration between leadership, addiction medicine providers, and frontline staff.

Equally important is the development of measurement systems capable of evaluating the total cost of care rather than focusing solely on pharmacy expenses. While medications such as extended-release buprenorphine may initially appear costly, research demonstrates that these expenses are often offset by reductions in hospitalizations, emergency services, detoxification admissions, and rehabilitation utilization (Oss, 2026). Tracking these broader outcomes allows organizations to demonstrate value to healthcare payers while supporting future participation in value-based care arrangements.

At CSBMG, continued efforts to strengthen behavioral health systems and improve access to evidence-based addiction treatment remain essential components of supporting healthier communities throughout Middle Georgia. Expanding access to recovery-oriented services, enhancing continuity of care, and supporting sustained treatment engagement can play a significant role in reducing the long-term impact of opioid addiction on individuals, families, and healthcare systems alike.

References

Oss, M. E. (2026, May 12). Finding ROI in MOUD. OPEN MINDS.